Bristol-Myers Squibb is on the auction block – maybe.
While there has been plenty of speculation over the last two days indicating that the big pharma could be a takeout target for some of its larger peers — including Pfizer, Johnson & Johnson, Sanofi and Novartis – a lot of that talk is based on two ideas: that Bristol-Myers is in dire straits and that activist investors are unhappy about it.
